In a pooled analysis of PETACC-8 and N0147, and a post hoc analysis of the PETACC-8, both included resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are independently associated with the decreased DFS in patients with pMMR, but not dMMR tumors (34, 35). This evidence concerns the gene KRAS and malignant colon neoplasm.